Read More Pharma Industry News Keymed Biosciences secures NMPA approval for Stapokibart in chronic rhinosinusitis treatment Keymed Biosciences Inc. (HKEX: 02162) has received a significant regulatory endorsement as the National Medical Products Administration (NMPA)… byPallavi MadhirajuDecember 23, 2024